# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Cantor Fitzgerald analyst Sarah James reiterates Health Catalyst (NASDAQ:HCAT) with a Overweight and maintains $16 price tar...
U.S. stock futures were slightly higher this morning, with the Nasdaq futures gaining by around 0.1% on Wednesday.
Keybanc analyst Scott Schoenhaus downgrades Health Catalyst (NASDAQ:HCAT) from Overweight to Sector Weight.
Cantor Fitzgerald analyst Sarah James reiterates Health Catalyst (NASDAQ:HCAT) with a Overweight and maintains $16 price tar...
Keybanc analyst Scott Schoenhaus maintains Health Catalyst (NASDAQ:HCAT) with a Overweight and lowers the price target from ...
Canaccord Genuity analyst Richard Close maintains Health Catalyst (NASDAQ:HCAT) with a Buy and lowers the price target from ...